Healthcare company Syncona announced that its companies, Gyroscope Therapeutics and Orbit Biomedical, would merge to create the first fully integrated retinal gene therapy platform with clinical, delivery and manufacturing capabilities. The merger would unite Orbit Biomedical's sub-retinal surgical platform with Gyroscope's retinal gene therapy platform and would retain the Gyroscope name. Syncona would own 82% of the enlarged company, which represented a holding value of £28.9m. "The merger ensures Gyroscope now has the key platform capabilities it requires to develop and deliver its therapeutics commercially. This marks an important step in fulfilling founding academics, David Kavanagh and Andrew Lotery's vision of widespread use of genetically defined treatments for dry AMD [age-related macular degeneration]," said Chris Hollowood, Chief Investment Officer of Syncona and Chair of Gyroscope, said: The company also appointed Khurem Farooq as CEO and Ian Clark as Non-Executive Director, both formerly of Genentech. Soraya Bekkali, who led Gyroscope into the clinic, would continue to lead the research and development organisation as President, Head of R&D, whilst Mike Keane and Susan Hill, who led the founding and launch of Orbit, would become Gyroscope's Chief Technology Officer and Chief Business Office, respectively. At 8:21am: (LON:SYNC) Syncona Ltd share price was +3.5p at 260p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.